Drug Interactions between Rapamune and valganciclovir
This report displays the potential drug interactions for the following 2 drugs:
- Rapamune (sirolimus)
- valganciclovir
Interactions between your drugs
No interactions were found between Rapamune and valganciclovir. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Rapamune
A total of 682 drugs are known to interact with Rapamune.
- Rapamune is in the following drug classes: mTOR inhibitors, selective immunosuppressants.
- Rapamune is used to treat the following conditions:
valganciclovir
A total of 237 drugs are known to interact with valganciclovir.
- Valganciclovir is in the drug class purine nucleosides.
- Valganciclovir is used to treat the following conditions:
Drug and food interactions
sirolimus food
Applies to: Rapamune (sirolimus)
ADJUST DOSING INTERVAL: Consumption of food can decrease the rate and extent of gastrointestinal absorption of sirolimus. Also, the consumption of grapefruit juice may result in increased sirolimus trough concentrations.
MANAGEMENT: Experts recommend that this drug be taken either at least one hour prior to eating or consistently with or without food to avoid variations in sirolimus blood levels. The manufacturer recommends against using grapefruit juice for dilution of sirolimus doses. Patients should be monitored for clinical and laboratory evidence of altered immunosuppressant effects.
References
- (2001) "Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories
valGANciclovir food
Applies to: valganciclovir
ADJUST DOSING INTERVAL: Food increases the bioavailability of ganciclovir from the prodrug, valganciclovir. In 16 HIV-positive subjects, the administration of valganciclovir 875 mg once daily with a high-fat meal containing approximately 600 calories resulted in a 30% increase in the steady-state area under the plasma concentration-time curve (AUC) and a 14% increase in the peak plasma concentration (Cmax) of ganciclovir, with no delay in the time to reach peak plasma concentration (Tmax). The mechanism is unknown.
MANAGEMENT: The manufacturer recommends that valganciclovir be taken with meals.
References
- (2001) "Product Information. Valcyte (valganciclovir)." Roche Laboratories
- Brown F, Banken L, Saywell K, Arum I (1999) "Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositiv volunteers." Clin Pharmacokinet, 37, p. 167-76
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.